Pfizer (PFE) is drawing attention for its attractive dividend yield of 6.7%, significantly outpacing the S&P 500’s average of 1.1%. For income-focused investors, this translates to nearly $1,700 in annual dividends from a $25,000 investment in Pfizer, compared to less than $300 from an average S&P stock. However, concerns are mounting following a recent earnings report that revealed a 9% decline in net income, raising questions about the sustainability of its dividend.
Despite a 5% year-over-year revenue increase, Pfizer’s adjusted earnings fell by 18%, prompting scrutiny of its ability to maintain its dividend payout. The company’s earnings per share (EPS) of $0.47 slightly exceeds its quarterly dividend of $0.43, resulting in a payout ratio exceeding 91%. Moreover, its free cash flow of $2.2 billion falls short of the $2.4 billion required for dividends, adding to investor anxiety.
While Pfizer remains committed to its dividend for now, investors should closely monitor its financial performance and cost-cutting efforts, as ongoing acquisitions could impact dividend sustainability. The current high payout ratio and cash flow concerns suggest that while a dividend cut isn’t imminent, it remains a possibility if financial conditions do not improve.
Source: fool.com